Terms: = Head and neck cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Treatment
36 results:
1. cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2.
Liu F; Tang L; Liu H; Chen Y; Xiao T; Gu W; Yang H; Wang H; Chen P
Cell Death Dis; 2024 Apr; 15(4):279. PubMed ID: 38637504
[TBL] [Abstract] [Full Text] [Related]
2. RASSF1A promotes radiosensitivity in nasopharyngeal carcinoma by promoting FoxO3a and inhibiting the Nrf2/TXNRD1 signaling pathway.
Si Y; Meng L; Zhang B; Wu Y; Du Q; Xu J; Qi J
Neoplasma; 2023 Oct; 70(5):633-644. PubMed ID: 38053374
[TBL] [Abstract] [Full Text] [Related]
3. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia.
Paiboonrungruang C; Xiong Z; Lamson D; Li Y; Bowman B; Chembo J; Huang C; Li J; Livingston EW; Frank JE; Chen V; Li Y; Weissman B; Yuan H; Williams KP; Ben Major M; Chen X
Redox Biol; 2023 Nov; 67():102901. PubMed ID: 37776708
[TBL] [Abstract] [Full Text] [Related]
4. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via keap1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract] [Full Text] [Related]
5. Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma.
Ramesh PS; Bovilla VR; Swamy VH; Manoli NN; Dasegowda KB; Siddegowda SM; Chandrashekarappa S; Somasundara VM; Kabekkodu SP; Rajesh R; Devegowda D; Thimmulappa RK
Free Radic Biol Med; 2023 Aug; 205():234-243. PubMed ID: 37328018
[TBL] [Abstract] [Full Text] [Related]
6. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
[TBL] [Abstract] [Full Text] [Related]
7. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract] [Full Text] [Related]
8. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
9. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
Yu W; Chen Y; Putluri N; Osman A; Coarfa C; Putluri V; Kamal AHM; Asmussen JK; Katsonis P; Myers JN; Lai SY; Lu W; Stephan CC; Powell RT; Johnson FM; Skinner HD; Kazi J; Ahmed KM; Hu L; Threet A; Meyer MD; Bankson JA; Wang T; Davis J; Parker KR; Harris MA; Baek ML; Echeverria GV; Qi X; Wang J; Frederick AI; Walsh AJ; Lichtarge O; Frederick MJ; Sandulache VC
Br J Cancer; 2023 Jun; 128(11):2013-2024. PubMed ID: 37012319
[TBL] [Abstract] [Full Text] [Related]
10. PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming.
Ma Y; Zhang X; Han X; Hao Z; Ji R; Li J; Guo W; Zhang Y; Guan F; Ma S
Mol Carcinog; 2023 Jun; 62(6):866-881. PubMed ID: 36988347
[TBL] [Abstract] [Full Text] [Related]
11. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in head and neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract] [Full Text] [Related]
12. Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing.
Falchetti M; Delgobo M; Zancanaro H; Almeida K; das Neves RN; Dos Santos B; Stefanes NM; Bishop A; Santos-Silva MC; Zanotto-Filho A
Comput Biol Med; 2023 Jan; 152():106347. PubMed ID: 36493734
[TBL] [Abstract] [Full Text] [Related]
13. Genetic alterations of keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma.
Islam SS; Qassem K; Islam S; Parag RR; Rahman MZ; Farhat WA; Yeger H; Aboussekhra A; Karakas B; Noman ASM
Cell Death Dis; 2022 Aug; 13(8):696. PubMed ID: 35945195
[TBL] [Abstract] [Full Text] [Related]
14. Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway.
Xia L; Gong M; Zou Y; Wang Z; Wu B; Zhang S; Li L; Jin K; Sun C
Oxid Med Cell Longev; 2022; 2022():9925919. PubMed ID: 35602105
[TBL] [Abstract] [Full Text] [Related]
15. Regulation of ferroptosis by noncoding RNAs: a novel promise treatment in esophageal squamous cell carcinoma.
Qiao G; Zhang W; Dong K
Mol Cell Biochem; 2022 Sep; 477(9):2193-2202. PubMed ID: 35449482
[TBL] [Abstract] [Full Text] [Related]
16. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma.
Yuan L; Li S; Chen Q; Xia T; Luo D; Li L; Liu S; Guo S; Liu L; Du C; Jia G; Li X; Lu Z; Yang Z; Liu H; Mai H; Tang L
Cell Death Differ; 2022 Aug; 29(8):1513-1527. PubMed ID: 35105963
[TBL] [Abstract] [Full Text] [Related]
17. Antioral Squamous Cell Carcinoma Effects of Carvacrol via Inhibiting Inflammation, Proliferation, and Migration Related to Nrf2/keap1 Pathway.
Liu H; Xu X; Wu R; Bi L; Zhang C; Chen H; Yang Y
Biomed Res Int; 2021; 2021():6616547. PubMed ID: 34212035
[TBL] [Abstract] [Full Text] [Related]
18.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract] [Full Text] [Related]
19. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract] [Full Text] [Related]
20. GULP1 regulates the NRF2-keap1 signaling axis in urothelial carcinoma.
Hayashi M; Guida E; Inokawa Y; Goldberg R; Reis LO; Ooki A; Pilli M; Sadhukhan P; Woo J; Choi W; Izumchenko E; Gonzalez LM; Marchionni L; Zhavoronkov A; Brait M; Bivalacqua T; Baras A; Netto GJ; Koch W; Singh A; Hoque MO
Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817372
[TBL] [Abstract] [Full Text] [Related]
[Next]
